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Abstract
Juvenile idiopathic arthritis (JIA) has long been assumed to be an autoimmune disease, triggered by
aberrant recognition of "self" antigens by T-cells. However, systems biology approaches to this
family of diseases have suggested complex interactions between innate and adaptive immunity that
underlie JIA. In particular, new data suggest an important role for neutrophils in JIA pathogenesis.
In this short review, we will discuss the new data that support a role for neutrophils in JIA, discuss
regulatory functions that link neutrophils to adaptive immune responses, and discuss future areas
of investigation. Above all else, we invite the reader to re-consider the use of the term
"autoimmunity" as applied to the family of illnesses we collectively call JIA.
Note on nomenclature
The nomenclature used to categorize children with
chronic arthritis has undergone considerable change over
the years covered by this review. The most widely accepted
classification scheme replaces the terms juvenile rheuma-
toid arthritis and juvenile chronic arthritis with the term
juvenile idiopathic arthritis. However, it is important for
the reader to note that the terms are not synonymous and
classification schemes do not completely overlap. This
leaves the reviewer with the vexing task of how to refer to
earlier studies that used different classification schemes.
For the sake of simplicity, clarity, and accuracy, we have
elected to use whatever terms were used by the authors of
the relevant studies in describing those studies, while
adhering to the internationally-accepted classification
scheme when speaking generically of chronic arthritis in
children.
Background
With the possible exception of the systemic-onset form
[1], juvenile idiopathic arthritis (JIA) has long been
assumed to be an "autoimmune" disease. The autoim-
mune theory of pathogenesis has tenaciously held its
position of unchallenged dogma in pediatric rheumatol-
ogy, despite serious limits in its ability to explain all the
known immunopathological phenomena and the paucity
of evidence for either a T- or B-cell driven response (see
below). At the same time, no competing theories for
pathogenesis have emerged, so the autoimmune theory
holds its ground by default. In this review, we will discuss
emerging evidence that demonstrates the importance of
neutrophils in regulating and informing the adaptive
immune response, suggesting, therefore, that innate
immunity may play a larger role in JIA pathogenesis than
has been previously thought. We will then summarize
new data from our laboratories that supports the hypoth-
esis that neutrophil activation in JIA is a primary patho-
genic event, and that involvement of the adaptive
immune system is downstream of that primary event.
This paper is not intended as a comprehensive review of
specific neutrophil function. Other authors have already
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rize relevant neutrophil biology in context, however, in
appropriate places in this text.
Limits of the T cell centered hypothesis
The presence of T cells within the inflamed synovium, the
frequency of antinuclear antibodies, and the association
of specific subtypes with specific HLA alleles [6] have all
been powerful arguments that the illnesses collectively
referred to as JIA represent an "autoimmune" disease
whose pathogenesis is rooted in the dysregulation of
mechanisms through which T cells distinguish "self" from
"non-self" [7]. However, over the past 20 years, little addi-
tional evidence has accumulated to support T-cell cen-
tered theories of pathogenesis. Furthermore, our
expanding knowledge has demonstrated equally plausible
explanations for some of the phenomena on which the
autoimmune hypothesis of JIA pathogenesis was built.
For example, T cells can be found in joints of adults with
gout [8,9] clearly demonstrating that the presence of T
cells within a joint does not require autoimmune activa-
tion. Moreover, an increasing body of evidence demon-
strates how T cells can be recruited to and activated in the
synovial space [10-12] without engagement of the T cell-
receptor-HLA complex, a process believed to be crucial in
JIA pathogenesis. The pathological meaning of autoanti-
bodies, and ANA in particular, in childhood arthritis
becomes less significant as we have established that the
presence of such autoantibodies is a common feature in
childhood [13,14] and not necessarily a sign of dysregu-
lated immunity. An additional Achilles heel of the
autoimmune theory of JIA pathogenesis is the fact that
HLA associations seen in one ethnic group are not found
in others, suggesting that HLA is an associative, not mech-
anistic, linkage to JIA[15]. Finally, and perhaps most
importantly, T cell-centered theories of JIA pathogenesis
have not provided the foundation for a single new treat-
ment for this disease. Current successful therapies are
either non-specific (e.g., methotrexate) or target proteins
that are critical elements of the innate immune response
(e.g., TNFα). Thus, there is an urgent need to rethink the
old paradigm and search more imaginatively for future
targets of therapy.
Neutrophils: seneschals of the adaptive immune response
Immunologists have long overlooked the neutrophil.
Lacking the elegant specificity of T and B cells and their
intricate "dance" with antigen processing cells and multi-
ple co-receptors, the neutrophil, with its, prepackaged
arsenal of inflammatory ordnance, short life span, and all-
too-well-recognized capacity to injure host tissue [16],
appeared to be the "loose cannon" of the immune system.
A more sophisticated model of neutrophil action has
evolved as we have come to understand better the com-
plex interplay between the innate and adaptive immune
systems.
Until recently, it was common to think separately about
innate and adaptive immunity. We typically think of
innate immunity as occurring early in an immune
response, being non-specific in nature, and completed at
the time specific, adaptive immune mechanisms come
into play. Although this view has the virtues of simplicity
and clarity (and thus provides a useful heuristic frame-
work), the truth is that innate and adaptive immunity dis-
play numerous points of intersection and co-regulation
[17,18].
Neutrophils provide one of the critical points of intersec-
tion between innate and adaptive immunity. Indeed, we
are now learning that neutrophils, like complement, play
a critical role in instructing and shaping almost every
aspect of the adaptive immune response.
Current states of knowledge suggest that an inflammatory
response must begin with the immune system's sensing
two classes of signals: tissue injury and the presence of a
foreign genome [19]. The presence of only one is inade-
quate to begin the process. Surgery, for example, injures
tissues, but excites a relatively modest inflammatory
response because of its being performed sterilely; com-
mensurate bacterial flora expose us daily to foreign
genetic material, but elicit little inflammatory response in
the absence of tissue injury [20]. Neutrophils play a criti-
cal role in sensing these binary signals, and, of most
importance to our understanding of JIA pathogenesis, can
serve as a central point of orchestration of subsequent
adaptive immune responses. Upon sensing the binary sig-
nals that trigger the inflammatory process, neutrophils
begin a program that determines whether there will be a
brisk, modest, or blunted immunologic response (see Fig-
ure 1). Release of neutrophil myeloperoxidase [21] and
anti-bacterial cationic proteins [22] up-regulates HLA
class II molecules and induces chemotaxis in monocytes.
Similar effects are induced on dendritic cells, mediated, in
part, by neutrophil release of TNFα[23,24]. However,
neutrophils' influence on adaptive immunity extends
beyond the early phases of antigen-presenting cell activa-
tion and immune response induction. Neutrophils also
release the TNF-related ligand, B lymphocyte stimulator
(BLyS), thus regulating the expansion and maturation of
B cells [25]. In a similar vein, neutrophil-derived IFNγ reg-
ulates the activation and expansion of T cells [26].
Thus, rather than being "downstream" of the putative
pathological events in JIA, neutrophils are arguably at the
very center. Furthermore, data from patients with known
autoinflammatory syndromes clearly demonstrate that dis-
rupted innate immunity can lead to clearly defined aber-Page 2 of 8
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field of pediatric rheumatology avoid a detailed study of
the neutrophil as we confront the limitations of T cell-cen-
tered theories of JIA pathogenesis? Isn't it time to look
upstream? These are rhetorical questions; it should be
obvious from the data that has emerged in the past 7 years
that we no longer can avoid a systematic examination of
neutrophil function in JIA, especially now that we have
improved tools and methodologies for doing so. In all
fairness, given the paucity of information that emerged
from early studies of neutrophils in JIA, it is easy to see
why this area was relatively neglected for so long.
Neutrophils in JRA/JIA: early studies
Early interest in neutrophils derived from the fact that
they are the most abundant cell within JRA synovial fluid
[30]. Several early studies examined neutrophil chemo-
taxis, with some showing no differences when JRA neu-
trophils were compared with controls [31] and others
showing increased motility of JRA neutrophils [32]
although the increases were observed only during periods
of active disease. There is a more extensive literature exam-
ining neutrophil function in adult rheumatoid disease,
although they, too, provide conflicting data. Studies of cir-
culating neutrophils from adults with rheumatoid arthri-
tis have generally reported absence of markers associated
with the activated state [33,34] (although there are con-
flicting data that suggest otherwise [35]) and normal
chemotaxis [36] (although, again, data from different
studies appear to conflict [37]). The applicability of these
findings to childhood-onset disease is uncertain when
thinking in traditional terms of neutrophil function. More
recent studies suggest that these studies were inconclusive
because neutrophils' regulatory potential may be more rel-
evant than their effector functions in JIA pathology.
With so much conflicting data, it is easy to see why pedi-
atric rheumatologists quickly dropped the neutrophil to
explore other potentially more productive areas of immu-
nology. By the 1990s, the neutrophil had all but disap-
peared from the pediatric rheumatology literature, with
the exception of a single study from Poland [38], a study
whose significance was unappreciated at the time. All of
this changed seven years ago, as an understanding of neu-
trophils regulatory potential began to unfold.
Evidence for chronic neutrophil activation in JIA/JRA
In 2000, Frosch and colleagues from the University of
Munster in Germany reported their investigations with
myeloid-related proteins (MRP-8 and -14) in juvenile
rheumatoid arthritis [39]. These proteins are made by
both monocytes and neutrophils and are released during
leukocyte interactions with endothelium [40]. These
authors reported a striking correlation between MRP-8
and -14 levels and disease activity in a cohort of children
with pauciarticular JRA. While these authors assumed that
monocytes were the cell of origin for the proteins, subse-
quent work from this same group (examining the related
protein, S100 A12) attributed the abundance of S100 pro-
teins in JRA sera to neutrophil activation [41]. Indeed,
neutrophil (or monocyte)-derived S100 proteins are
beginning to emerge as a potentially useful clinical
biomarker to monitor response to therapy in children
with JIA. At the risk of generating some healthy contro-
versy, it is worth pointing out that no reliable T- or B-cell
based biomarker for response to therapy in JIA has
emerged in the past 20 years.
Before the publication of the Frosch and Foell papers, we
had posited that JIA immune pathogenesis very likely
involves complex interactions between innate and adap-
tive immunity [42] and ongoing work from our group has
aimed at elucidating those interactions [43]. We have
therefore undertaken a "systems biology" [44,45]
approach to polyarticular JIA in an effort to obtain the
"global view" of these interactions [46]. In a preliminary
study, designed largely to develop methodologies [43], we
examined gene expression profiles of whole blood buffy
coats in a small group (n = 9) of children with active JRA.
In that study, we were quite surprised to see over-expres-
sion of genes either expressed by neutrophils (e.g., ferritin
heavy and light chains, N-formyl peptide receptor) or reg-
ulating neutrophil function (e.g., IL-8) in children with
JRA. These data were consistent with the data emerging
Interplay of innate and adaptive immunity showing multiple actions of neutrophils on the adaptive immune responseFigure 1
Interplay of innate and adaptive immunity showing multiple 
actions of neutrophils on the adaptive immune response. 
This figure is not intended to be comprehensive. Rather it 
shows in a highly-simplified fashion the role of neutrophils in 
informing the adaptive immune response and some of the 
mediators through which those effects are regulated.
BLyS
B cell activation and maturation
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Monocyte and dendritic cell maturation, 
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an important role in JRA/JIA pathogenesis.
We next performed gene expression profiling on neu-
trophils of 25 children with JRA, 15 of whom were studied
during periods of active and inactive disease as defined by
Wallace and colleagues [47]. In that study, we demon-
strated aberrant patterns of gene expression in neutrophils
of children with polyarticular JIA, even when their disease
was inactive [48]. Indeed, hierachical clustering analysis,
a method for asking, "Which group is most like the other
group?"scattered patients with active and inactive disease
indistinguishably, as shown in Figure 2. Even more inter-
esting were in silico models of the differentially-expressed
genes (Figure 3), which showed clusters of IFNγ and IL-8-
related genes, the significance of which will be explained
shortly. Subsequent work from our laboratory has shown
that these expression abnormalities persist even when
children fit consensus criteria for remission (unpublished
data). This contrasts with what we have reported in
peripheral blood mononuclear cells of children with JIA,
where gene expression profiles normalize after therapy
[49]. The obvious question is, "What is this defect, and
what can we do about it?"
Neutrophils as oscillators
The key as to where the defect in JIA/JRA neutrophils
might lie emerged from the in silico modeling of the gene
expression data. As noted above, computer modeling of
the functional relationships between the different genes
suggested linked networks of IL-8 and IFNγ-regulated
genes. The significance of this finding may lie in the
underlying dynamic properties of cell chemistry.
Oscillations are found throughout nature, from bacteria
to man [50]. Oscillations show three characteristics: fre-
quency, amplitude, and phase; examples of these are the
heart rate, stroke volume, and relative timing of the open-
ing of the heart valves. In addition to this macroscopic
example, oscillations in calcium signaling, mitosis, and
hormone action have been studied.
Neutrophil oscillations were first reported in the late
1980s (e.g., Jager et al [51]). Since that time, a broad vari-
ety of neutrophil oscillations has been reported and their
relationship to human disease documented [52]. These
oscillations are not peripheral events in cell behavior, but,
rather, are a central element of neutrophil activation, and
therefore potentially critical to our understanding human
inflammatory diseases.
Renewed interest in the phenomenon of neutrophil oscil-
lations began with observations demonstrating physical
proximity between β2 integrins and other cell-surface
receptors, which allowed the integrins to serve as signal
transducers for glycophosphatidylinositol (GPI)-linked
proteins. Furthermore, when receptor proximity on living
cells (e.g., between the complement receptor CR4 and
urokinase plasminogen activator receptor [uPAR]) was
measured with resonance energy transfer microscopy, it
was found to oscillate in time[53]. The fact that all of the
CR4 and uPAR molecules either come into proximity or
move away from each other simultaneously implies bio-
logical coherence in receptor action; the receptors are not
behaving as individual signaling units but as a collective.
Moreover, the period of CR4-uPAR oscillation was similar
to that reported previously by other research groups for
other neutrophil oscillators. Furthermore, the shape of
the oscillatory waves could be modulated by suboptimal
doses of kinase and phosphatase inhibitors, indicating
that the dynamic uPAR-CR4 interactions are coupled with
oscillatory signal transduction machinery. This suggests
that the structural and functional oscillations of neu-
trophils are tied to the same fundamental chemical oscil-
lator. The heterogeneity of the oscillators, such as receptor
properties, membrane potential, shape, actin, etc would
simply reflect the experimental readouts employed.
Subsequent work in the Petty laboratory has directly
linked cell metabolism, oscillatory phenomena, and cell
Hierarchical cluster analysis of gene expression profiles in children with polyarticu ar, RF-n gative JRAFigu  2
Hierarchical cluster analysis of gene expression profiles in 
children with polyarticular, RF-negative JRA. Gene expres-
sion profiles are compared with those of healthy controls, 
shown on the left of the grid. Children with active disease 
("A") scatter through the heat map with children with 
"responsive" ("R" = "inactive") disease and children who have 
shown a "partial" response to therapy ("P" = have met 
ACR30 criteria). From Jarvis et al, Arthritis Res Therapy 2006. 
The authors retain the copyright for this material.Page 4 of 8
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tuations in NAD(P)H levels, which respond parallel to,
but 180° out of phase, with ATP. Furthermore, because
NAD(P)H is fluorescent, fluctuations can be measured
without perturbing the cells (although NADH and
NADPH cannot be distinguished spectroscopically). Sub-
sequent work in the Petty laboratory using NAD(P)H
autofluorescence has shown that (1) metabolic oscilla-
tions drive receptor signaling and receptor oscillations;
(2) variations in NAD(P)H amplitude and frequency are
carried "downstream" to other functional, oscillatory phe-
nomena such as superoxide and nitric oxide production;
(3) the period of NAD(P)H oscillations is tightly linked to
the key event in neutrophil activation, glucose influx.
A wide variety of biological materials are known to influ-
ence intracellular calcium signaling. Similarly, this group
has discovered numerous materials that influence the
amplitude or frequency of calcium and/or metabolic
oscillations. These include fMLP, immune complexes,
IFNγ, TNFα, and others [55,56]. It is important to note
that specific agents regulate specific aspects of the oscilla-
tory phenomena. Specifically, wave amplitude and wave
frequency are regulated independently, and the mecha-
nisms that regulate each are stringently insulated from
one-another. Some of the relevant mediators can be sum-
marized as follows:
1. IFNγ and PMA trigger amplitude modulation of the
oscillations.
2. TNFα, IL-8, fMLP, and immune complexes cause cal-
cium and metabolic oscillations to double in frequency.
In silico modeling derived from Pathway Assist software analysis of differential gene expression in JRA neutrophils compared with healthy control subjectsFigur  3
In silico modeling derived from Pathway Assist software analysis of differential gene expression in JRA neutrophils compared 
with healthy control subjects. Note clusters of IFNγ-(lower right) and IL-8- (lower left) regulated genes. From Jarvis et al, 
Arthritis Res Therapy 2006. The authors retain the copyright for this material.
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IL-6, double oscillation frequency, but only during con-
current amplitude modulation, e.g., with IFNγ.
With this as a background, we get back to interpreting the
gene expression profile in JRA neutrophils. The patterns of
IL-8 and IFNγ-regulated gene expression suggested that it
would be fruitful to examine other fundamental cellular
processes regulated by those mediators, specifically
NAD(P)H oscillations. The findings suggested a funda-
mental breakdown of the processes that insulate fre-
quency and amplitude regulation in JRA neutrophils, as
shown in Figure 4. That is, agents that normally evoke
only increases in NAD(P)H frequency (LPS, immune
complexes), induced both frequency and amplitude
enhancement in a subset of JRA neutrophils. This defect
was observed in patients with both active and inactive dis-
ease. Thus, we assume that this defect may be primary,
although the possibility that it is caused or driven by more
fundamental aberrations in adaptive immunity cannot be
excluded.
Redefining the pathogenic paradigm and exploring the 
future
It is time to ask whether the T cell deserves the place it has
held for so long in the center of JIA pathogenic paradigms.
While there is insufficient data to replace the central place
of the T cell with the neutrophil (although Figure 1
accounts for the known data as well to us than the T cell
centered paradigm), it is time to give neutrophils their due
place. New data from multiple laboratories, using tech-
niques as diverse as genomics, in silico modeling, and sin-
gle-cell microscopy, all suggest that we have overlooked
the critical role neutrophils may play in JIA pathogenesis.
Furthermore, these data account for observed phenomena
not explainable by T cell-centered hypotheses (e.g., the
applicability of S100 proteins as biomarkers of response).
Furthermore, they account for the known involvement of
adaptive immunity far better than T cell-centered hypoth-
eses account for the known involvement of the innate
immune system, although there is reason to believe the
interaction is bi-directional [57]. Indeed, the efficacy of
anti-inflammatory therapies, such as anakinra [58], MRA
[59], thalidomide[60] (a powerful suppressor of neu-
trophil function), as well as T cell inhibitory therapy
(abatacept, cyclosporine) suggests that distorted cross-talk
innate between adaptive immunity is a critical element in
JIA pathogenesis. We would simply argue that this does
not necessarily imply that the dysfunctional relationship
starts with T cells.
There is still much to do. It is very likely that we will need
rigorous applications of systems biology approaches and
ongoing cooperation between laboratories invested in
both innate and adaptive immunity to unravel the com-
plexities that are only now coming into focus. It is clear
that we know little of the molecular basis of disease
pathology and nothing of the etiology of any of the forms
of JIA. Maybe a short moratorium on the word, "autoim-
mune," as applied to this family of diseases, is in order,
since use of the word suggests that we already know where
the relevant immunopathogenic events may reside. Above
all, we need to be bold and creative in our thinking, ready
to cut loose from comfortable paradigms, humble in
admission of what we still don't know, and persistent in
our determination to get better answers for hundreds of
thousands of children and young adults with arthritis.
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